Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMPART: Adjuvant Durvalumab +/- Tremelimumab in Resected RCC
NCT03288532Phase 3Recruiting
- Sponsor
- University College London
- Start
- Jul 2018
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in renal cell carcinoma (RCC), sponsored by University College London. Started Jul 2018; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03288532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288532.